Allogene Raises $175 Million in Discounted Stock Offering

Event summary

  • Allogene Therapeutics priced an underwritten public offering of 87.5 million shares at $2.00 per share, raising gross proceeds of $175 million.
  • The offering includes a 30-day option for underwriters to purchase up to 13.125 million additional shares.
  • Proceeds will be used for general corporate purposes, including clinical trial expenses, R&D, and G&A.
  • The offering is expected to close on or about April 16, 2026.
  • Goldman Sachs, Jefferies, TD Cowen, Piper Sandler, William Blair, Baird, Canaccord Genuity, and TPG Capital BD are involved as underwriters.

The big picture

This capital raise underscores the ongoing challenges faced by clinical-stage biotech companies in accessing public markets, particularly those reliant on complex and expensive cell therapy programs. The discounted pricing signals a cooling investor sentiment towards the AlloCAR T space, potentially impacting the development timelines and funding strategies for other companies in the field. The $175 million injection provides Allogene runway, but the terms suggest a significant valuation reset.

What we're watching

Valuation Pressure
The $2.00 offering price represents a significant discount to Allogene's pre-announcement trading levels, suggesting investor concern about the company's near-term prospects and potentially impacting future financing options.
Clinical Trial Progress
The allocation of proceeds towards clinical trial expenses highlights the critical importance of upcoming data readouts; any setbacks or delays could trigger further downward pressure on the stock.
Underwriter Exercise
Whether the underwriters exercise their option to purchase the additional shares will be an indicator of their confidence in Allogene's future performance and the overall market appetite for the offering.

Related topics

Biotechnology